NEW YORK (GenomeWeb News) – Agilent Technologies today announced a collaboration with Florida International University to develop methods for the identification and characterization of designer drugs.

Agilent is working with FIU's department of chemistry and biochemistry and its International Forensics Research Institute and is currently focused on developing and validating methods for rapid forensic screening and analysis to expand the capabilities of drug screening techniques using immunoassays, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.